Botanix Pharmaceuticals Limited
BXPHF
$0.02
$0.007.14%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 243.70% | 249.61% | 4,303.82% | 4,168.38% | 210.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 243.70% | 249.61% | 4,303.82% | 4,168.38% | 210.96% |
| Cost of Revenue | 251.92% | 257.97% | 396.67% | 381.53% | -6.83% |
| Gross Profit | 236.30% | 242.08% | 1,378.03% | 1,339.19% | 381.87% |
| SG&A Expenses | -11.21% | -9.68% | 44.19% | 39.78% | 589.82% |
| Depreciation & Amortization | 6.08% | 7.90% | 6.86% | 3.60% | 1,639.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11% | 2.85% | 56.07% | 51.30% | 439.35% |
| Operating Income | 24.66% | 23.36% | -5.91% | -2.67% | -484.97% |
| Income Before Tax | 29.15% | 27.93% | -8.25% | -4.94% | -542.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.15% | 27.93% | -8.25% | -4.94% | -542.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.15% | 27.93% | -8.25% | -4.94% | -542.17% |
| EBIT | 24.66% | 23.36% | -5.91% | -2.67% | -484.97% |
| EBITDA | 25.36% | 24.08% | -5.88% | -2.64% | -476.19% |
| EPS Basic | 44.21% | 43.01% | 0.00% | 3.51% | -427.78% |
| Normalized Basic EPS | 44.07% | 43.10% | 0.00% | 2.78% | -436.36% |
| EPS Diluted | 44.21% | 43.01% | 0.00% | 3.51% | -427.78% |
| Normalized Diluted EPS | 44.07% | 43.10% | 0.00% | 2.78% | -436.36% |
| Average Basic Shares Outstanding | 26.30% | 26.30% | 8.11% | 8.11% | 19.73% |
| Average Diluted Shares Outstanding | 26.30% | 26.30% | 8.11% | 8.11% | 19.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |